FIELD: medicine.
SUBSTANCE: invention refers to a method of treating neurodegenerative disorders, neuropsychiatric disorders, as well as psychosis secondary to neurodegenerative disorders by introducing a compound of formula 
or its tartrate salt into a patient.
EFFECT: treating neurodegenerative disorders, neuropsychiatric disorders, psychosis secondary to neurodegenerative disorders by introducing the compound of formula representing the properties of the inverse 5-HT2A and 5-HT2C receptor agonist, or its tartrate salt.
15 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS, USED AS THERAPEUTICS FOR NEURODEGENERATIVES DISEASES | 2004 |
|
RU2332401C2 |
| THE SELECTIVE INVERSE AGONISTS OF SEROTONIN RECEPTORS AS MEDICATION TO CURE DISEASES | 2005 |
|
RU2442607C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508096C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
| APPLICATION OF N-DISMETILKLOSAPINE FOR HUMAN NEUROPSYCHIATRIC DISEASES TREATMENT | 2004 |
|
RU2336879C2 |
| COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
| THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
| NEW USING (R)-(-)-2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2001 |
|
RU2278663C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2743513C2 |
| TARGET DRUG WITH NEW COMPOSITIONS, COMBINATIONS AND METHODS | 2018 |
|
RU2760558C2 |
